These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31452150)

  • 1. Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review.
    Petitcollin A; Bensalem A; Verdier MC; Tron C; Lemaitre F; Paintaud G; Bellissant E; Ternant D
    Clin Pharmacokinet; 2020 Jan; 59(1):37-49. PubMed ID: 31452150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of therapeutic monoclonal antibodies.
    Dirks NL; Meibohm B
    Clin Pharmacokinet; 2010 Oct; 49(10):633-59. PubMed ID: 20818831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.
    Bajaj G; Suryawanshi S; Roy A; Gupta M
    Br J Clin Pharmacol; 2019 Sep; 85(9):2045-2058. PubMed ID: 31140642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
    Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.
    Chen X; Hickling T; Kraynov E; Kuang B; Parng C; Vicini P
    AAPS J; 2013 Oct; 15(4):1141-54. PubMed ID: 23990500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of altered endogenous IgG on unspecific mAb clearance.
    Fuhrmann S; Kloft C; Huisinga W
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.
    Kathman S; Thway TM; Zhou L; Lee S; Yu S; Ma M; Chirmule N; Jawa V
    AAPS J; 2016 Mar; 18(2):424-31. PubMed ID: 26786568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
    Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    Protein Cell; 2018 Jan; 9(1):15-32. PubMed ID: 28421387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies.
    Grabowski T; Reijers JAA; Burmańczuk A; Chełmońska-Soyta A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):585-589. PubMed ID: 30810916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
    Ternant D; Azzopardi N; Raoul W; Bejan-Angoulvant T; Paintaud G
    Clin Pharmacokinet; 2019 Feb; 58(2):169-187. PubMed ID: 29802542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.
    Dreesen E; Gils A; Vermeire S
    Curr Drug Targets; 2018; 19(7):757-776. PubMed ID: 26953243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides.
    Datta-Mannan A
    Drug Metab Dispos; 2019 Oct; 47(10):1100-1110. PubMed ID: 31043438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.